文献速递肾小球疾病

C3肾小球病补体通路基因分析

Genetic analysis of the complement pathway in C3 glomerulopathy.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究对43例散发性C3肾小球病(DDD 10例,C3GN 33例)及24例免疫复合物介导的MPGN患者进行11个候选替代途径基因的靶向基因组富集和大规模平行测序。共鉴定4个新变异和16个罕见变异,其中1个可能致病,19个意义不明。DDD、C3GN和免疫复合物介导MPGN中遗传性补体替代途径调控缺陷频率分别为50%、27%和17%。

要点

  • C3肾小球病中补体替代途径基因变异常见,CFH、CFI、CD46和C3基因最常累及。
  • DDD中遗传性补体调控缺陷频率达50%,高于C3GN的27%和免疫复合物MPGN的17%。
  • 多数变异意义不明,仅1个可能致病,基因变异携带者与无变异者临床表现相似。

核心结论

  • 准确的基因筛查有助于理解C3肾小球病的发病机制,致病性分类对患者管理、预后或治疗建议很重要。

研究设计与样本

  • 对43例散发性C3肾小球病(DDD 10例,C3GN 33例)和24例免疫复合物介导的MPGN患者,用靶向基因组富集和大规模平行测序筛查11个候选替代途径基因。

主要发现

  • 共鉴定4个新变异和16个罕见变异,其中1个可能致病,19个意义不明。
  • 3个变异据报道导致功能缺陷并有支持证据。
  • CFH、CFI、CD46和C3基因变异最常检出。
  • 遗传性补体替代途径调控缺陷在DDD、C3GN和免疫复合物介导MPGN中的频率分别为50%、27%和17%。
  • 无论组织学类型,携带可能致病或意义不明变异的患者与无变异者临床表现相似。

临床怎么用

  • 对C3肾小球病患者可考虑补体替代途径基因筛查以辅助发病机制评估和致病性分类。

局限性

  • 多数变异意义不明,致病性解释受限;样本量有限,尤其DDD仅10例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: C3 glomerulopathy often presents with a membranoproliferative glomerulonephritis (MPGN) pattern, and is principally caused by unrestricted activation of the complement alternative pathway. Genetic abnormalities of the complement system critically implicate in the pathogenesis of C3 glomerulopathy, but a systemic profile remains open, especially in Asia. METHODS: In this study, we completed a comprehensive screen of 11 candidate alternative pathway genes by using targeted genomic enrichment and massively parallel sequencing on 43 patients with sporadic C3 glomerulopathy, which were classified as dense deposit disease (DDD; n = 10) and C3 glomerulonephritis (C3GN; n = 33) cases. An additional 24 patients with immune complex-mediated MPGN were also enrolled. RESULTS: In total, 4 novel and 16 rare variants were identified: one was classified as likely pathogenic, and the remaining 19 were of uncertain significance. Three variants reportedly led to functional deficiency with supporting evidences. Variants in the CFH, CFI, CD46 and C3 genes were most frequently detected. A defective control of the complement alternative pathway due to hereditary abnormalities was found at frequencies of 50%, 27% and 17% in DDD, C3GN and immune complex-mediated MPGN, respectively. Irrespective of histological type, the patients with likely pathogenic and uncertain significant variants were clinically similar to those without. CONCLUSIONS: Accurate genetic screening can give rise to progress in understanding the pathogenesis of C3 glomerulopathy, and the correct assignment of pathogenicity classification is of great importance for better patient care and prognostic or therapeutic advice.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhao W, Ding Y, Lu J, et al. Genetic analysis of the complement pathway in C3 glomerulopathy. Nephrol Dial Transplant. 2018. PMID: 29566171. doi:10.1093/ndt/gfy033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。